Category: Insights

Read the latest news from Beghou Consulting, as well as our experts’ views on trends and challenges in the life sciences industry.

Dan Wetherill on using analytics to boost patient compliance

Patient compliance has become a more acute challenge during the coronavirus pandemic. In this article in Pharmaceutical Executive, Beghou Consulting Partner Dan Wetherill explains how biopharmaceutical companies can play a significant role in improving patient compliance by leveraging their advanced analytics capabilities and increasing collaboration with caregivers.
Read More »

Piotr Kula on how to overcome pharma’s data overload

Life sciences companies are faced with overwhelming amounts of data. As they seek to organize, manage and extract insights from this data, a cross-functional team can help better execute data strategy, ensure compliance and meet analytics goals. Associate Partner Piotr Kula describes in PM360 how to address this data overload.
Read More »

Esin Izat on using marketing research to inform brand stories

The brand story is an essential component of product launch, informing everything from go-to-market strategy to color schemes and logos. It can also successfully position a product in a competitive marketplace. Manager Esin Izat, leader of our marketing research practice, describes in PharmaVOICE how to use marketing research to craft compelling brand stories.
Read More »

Jon Hesby, Kevin Frymire and Rob Lien on navigating the COVID-19 pandemic

While pharmaceutical commercial teams navigating the COVID-19 pandemic don’t face the same life-or-death decisions the Apollo 13 team did 50 years ago, they are still responding to rapidly evolving circumstances in an uncertain environment. In Med Ad News, Partner Jon Hesby and Associate Partners Kevin Frymire and Rob Lien share three lessons from the Apollo 13 story that can help pharma companies today.
Read More »

Dan Schulman addresses key considerations in orphan drug commercialization

Orphan drugs are different than mass-market therapies — and so is their commercial strategy. Orphan drug manufacturers should engage patients throughout research, development and commercialization — and hire specialized sales forces market the therapy to the most relevant physicians. Associate Partner Dan Schulman describes in Med Ad News the steps orphan drug manufacturers can take to ensure their life-saving treatments reach patients as quickly as possible.
Read More »